DPP-4 inhibitors are considered effective for the treatment of type 2 diabetes mellitus in Asian patients, including Japanese patients, who often have insufficient insulin secretion [11,12], in contrast to Caucasian patients who usually have insulin resistance. Here, DPP4 is linked to diabetes mellitus.